The vaccine is jointly developed by Indonesia’s state-owned pharmaceutical holding company PT Bio Farma and China-based biopharmaceutical company Sinovac Biotech and other stakeholders from the United Arab Emirates (UAE) and the Republic of Korea (RoK), the President told reporters during his working visit to West Java province on August 11.
On July 21, a total of 2,400 doses of vaccine from Sinovac were handed over to Bio Farma for the trial of the third phase.
According to Honesti Basyir, Bio Farma CEO, the clinical trial of the vaccine is scheduled to run for six months, so it is targeted to be completed in January 2021.
If the clinical trial goes well, Bio Farma will produce it in the first quarter of 2021, he said, adding that the company has prepared production facilities with a maximum production capacity of 250 million doses per year.
Along with the vaccine development, Bio Farma has also conducted four other research to respond to the spread of the SARS-CoV-2 virus, including producing realtime polymerase chain reaction, convalescent plasma therapy, producing mobile BSL 3 laboratories, and manufacturing viral transport media./.
CPV (Source: VNA)
- Indonesia plans to produce COVID-19 vaccine
- Lastest COVID 19 vaccine updates FDA says Pfizer BioNTech safe effective China s Sinovac vaccine is 97 percent effective
- Why nearly 30 fully vaccinated people and scientist on China’s Sinovac have died with COVID-19
- Indonesian nurse dies 9 days after receiving Chinese vaccine
- Covid-19 vaccine production plant to be developed in Hanoi
- Over 900 more volunteers get Nano Covax shots in third phase of clinical trial
- Second clinical trial phase of Vietnamese-made vaccine carried out in Long An
- No expansion of clinical trial of Vietnam’s Nano Covax vaccine candidate
- Phase 3 clinical trial of Vietnamese-made vaccine to be conducted in 2021
- Vietnam's Covid-19 vaccine completes 50% of phase 2 trial
